DeepCyte will present at the Applied Pharmaceutical Analysis Conference highlighting DeeTox, its Single-Cell Mechanistic AI platform for cell-specific mechanism prediction.
Published
Signal category
Presence & Recognition
Quote
“DeepCyte will present at the Applied Pharmaceutical Analysis (APA) Conference highlighting DeeTox, DeepCyte’s Single-Cell Mechanistic AI platform for cell-specific mechanism prediction.”
— DeepCyte team
Company
DeepCyte
Single-Cell toxicology for drug development: Detect, Predict and Explain Drug Toxicity in Human Cells.
- Industry
- Biotechnology Research
- Location
- Copenhagen, DK
- Company size
- 9 employees
DeepCyte combines high-throughput single-cell metabolomics with AI to detect, predict and explain drug toxicity in human cells, before molecules reach patients. Drug Toxicity is a leading cause of clinical-trial failure and drug withdrawal, costing the industry billions each year. Animal models, high-throughput screening, and bulk assays often miss how real human cells respond. Regulators including the FDA & EMA are pushing toward human-relevant, mechanism-aware safety testing. DeepCyte's DeeTox AI platform uses laser-based sampling and mass spectrometry to profile the metabolism of individual human cells, generating Atlas-Scale, AI-ready datasets. Our first AI product, evaluated on 100 held-out drugs, predicted 17 detailed toxicity mechanisms at 94% accuracy. Our company is built on more than 10-years of academic research, with 3 patent applications filed, and a $1.5M round closed on January 2026. We operate from San Diego and Copenhagen. Follow us for research, product, and company updates.
Founded 2025